NCT02420392View on ClinicalTrials.gov

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

NACompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin

8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Seoul National University Hospital

OTHER